Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
102 hedge funds and large institutions have $307M invested in Arena Pharmaceuticals Inc in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 19 reducing their positions, and 45 closing their positions.
169% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $4.87M
147% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 19
88% more capital invested
Capital invested by funds: $163M → $307M (+$144M)
19% less funds holding
Funds holding: 126 → 102 (-24)
51% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 45
Top Buyers
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$33.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.79M |
| 4 |
Millennium Management
New York
|
+$6.98M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.62M |
Top Sellers
| 1 |
SAM
Senzar Asset Management
New York
|
-$2.85M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$497K |
| 3 |
Norges Bank
Oslo,
Norway
|
-$494K |
| 4 |
Two Sigma Investments
New York
|
-$457K |
| 5 |
QI
QS Investors
New York
|
-$452K |
ARNA Hedge Fund Activity: Q2 2017 in Review
102 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q2 2017, worth a combined $307M — up 88% from $163M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of ARNA and 22 opened new positions — a net loss of 23 holders — while 19 trimmed existing stakes and 47 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $33.5M. The largest seller was Senzar Asset Management, exiting entirely with an estimated $2.85M sold.
- 102 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q2 2017, down from 126 in Q1 2017.
- Funds reported $307M of Arena Pharmaceuticals Inc stock for Q2 2017, up 88% quarter-over-quarter.
- 22 funds opened new Arena Pharmaceuticals Inc positions in Q2 2017 and 45 closed out, a net change of -23 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q2 2017 was Great Point Partners, an estimated $33.5M added.
- The largest Arena Pharmaceuticals Inc seller in Q2 2017 was Senzar Asset Management, an estimated $2.85M sold.
Based on aggregated 13F filings for Q2 2017.